Esperion Therapeutics Inc. held its annual meeting on May 29, 2025. Stockholders approved the election of Class III director nominees Jay P. Shepard and Seth H.Z. Fischer to the Board of Directors. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. An amendment to the 2022 Stock Option and Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance by 6,250,000 shares was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.